Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX 5 15 SULFITE FREE IN DEXTROSE 15 IN PLASTIC CONTAINER versus NOVAMINE 8 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX 5 15 SULFITE FREE IN DEXTROSE 15 IN PLASTIC CONTAINER versus NOVAMINE 8 5.
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER vs NOVAMINE 8.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and nitrogen balance; dextrose provides caloric support. Electrolytes maintain acid-base and fluid balance.
Novamine 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in patients who cannot obtain adequate nutrition enterally.
Intravenous infusion. Dose individualized based on protein and calorie requirements. Typical adult dose: 500-2000 mL/day, providing 5% amino acids (50 g/L) and 15% dextrose (150 g/L). Infusion rate not to exceed 0.1 g/kg/hour of amino acids.
500 mL to 2000 mL intravenously per 24 hours, typically infused at a rate of 20 to 40 mL/hour; adjust based on metabolic and clinical response.
None Documented
None Documented
Not applicable as a composite; individual amino acids: 0.5–2 h, dextrose: 1.5–2.5 h. Clinical context: continuous infusion reaches steady state within 4–6 h.
Variable; amino acids have short t1/2 of minutes to hours. Clinical context: continuous infusion maintains steady state; elimination depends on metabolic demand and organ function.
Renal excretion of amino acids and dextrose metabolites; 100% eliminated via kidneys as urea, CO2, and water. Biliary/fecal negligible.
Renal: >95% as amino acids and metabolites. Biliary/fecal: <5%.
Category C
Category C
Parenteral Nutrition
Parenteral Nutrition